The mHealth Grand Tour
On September 3rd a group of riders will set out on a gruelling road trip from Brussels to Geneva. This ride will last 9 days, will cover 1500km, including nearly 22,000m of ascent, as the riders traverse Europe. This unique group of riders, professional and amateur, have a single unifying goal–improving the lives of people with diabetes.
Globally 387 million people have diabetes–by 2035 this will rise to 592 million. Diabetes caused 4.9 million deaths in 2014 which means that every seven seconds a person dies from diabetes. The management of chronic diseases such as diabetes is costly. It is estimated that the global cost of the management of diabetes is an estimated US$612 billion in health expenditure (2014)–11% of total spending on adults. Mobile health solutions have the potential to help healthcare providers deliver better and more efficient healthcare, however these solutions are complex, requiring a number of technologies that can produce meaningful clinical data outside the hospital environment which can then be transmitted to the health professional.
The mHealth Grand Tour is an “observational study”, developed to demonstrate how innovative products and technical solutions can help the challenges of managing diabetes. It provides an extraordinary and challenging environment for technology solution providers to test a range of technical solutions that provide personalised medical support to the riders. After the race is over, the data collected will be analysed as part of a retrospective observational study and the results will be shared before the end of 2015.
ICON is proud to support two riders in the mHealth Grand Tour–Mr James O’Reilly and Mr Frans Luijendijk–both of whom have type 1 diabetes, and we will be following their progress as they cycle the 1500km. Supporting this unparalleled event also allows us to work with technology partners who are experts in the area of diabetes management. Though our collaboration, we will gain unique insights into the technical, medical and regulatory challenges that are facing the development of mobile health solutions which will help us to design and fine tune a remotely monitored clinical trial in one of the most prevalent chronic disease areas affecting the world today.
More importantly this tour gives ICON the opportunity to engage with the empowered patient who is using wearables and other technological advancements to monitor and manage their own health in a way that was not conceived of previously. Although it is widely accepted that the use of wearable technology in clinical trials has the potential to be one of the most disruptive innovations in drug development, currently the use of wearable technology by big pharma in clinical trials is limited and it would appear that we can learn a lot about the value and practical use of wearables from our patients.
When asked why this event was so important James responded: “I see my participation in the 2015 mHealth Grand Tour as a great opportunity for me to assist in the development of technical solutions that have the possibility to improve the quality of life of those living with chronic diseases worldwide. As a Type 1 Diabetic, I myself am hugely reliant on technology to manage my disease. I use blood glucose metres to test my sugar levels multiple times a day. I wear an insulin pump to administer insulin 24 hours a day. I also use apps on my mobile telephone to help me count carbohydrates, calculate insulin dosages and log diaries of information. While the use of technology can greatly increase the accuracy w ith which I can manage my Diabetes, the requirement to understand, use and care for all of these pieces of technology can also become a burden and a source of stress. Studies such as the one that will be carried out during the health Grand Tour will lead to the development of further technical solutions that will reduce the mental effort required to manage this disease and the inherent burden that is living with Type 1 Diabetes. I look forward to a future where a patient centric approach is at the forefront of managing chronic diseases.”
Frans added that the more technology can take over managing this difficult disease, the easier it will become for him. “Anything we can do as patients to help advance technology, the faster fully automatic diabetes management solutions will be available. The difference the continuos glucose sensor already made to my life over the last three years is incredible. I can’t wait for a future where the only thing I need to do is change the cartridge of my insulin pump in time.”
We wish them both a successful tour as they embark on this ground breaking innovation journey which ICON anticipates will provide insights into the development of technological solutions that will help create more patient centric clinical trials.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
- EU Regulations
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Digitising COAs
-
Linguistic validation of Clinical Outcomes Assessments
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Supporting a top 10 pharma to transition to Veeva Vault platform
-
Transforming the R&D Model to Sustain Growth
-
Digitising COAs
-
Value Based Healthcare
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
US payers and PROs
-
Blog
-
Videos
-
Webinar Channel